Testing a precise radiation boost for head and neck tumours
Tests a precise radiation boost in adults with head and neck cancer.
Plain-language title generated from the registry record
Registry title: Stereotactic Radiosurgery in Patients With Head and Neck Region Tumours
Key facts
- Where
- Gliwice, PolandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06472570, who can take part
Where in Poland
- 1st Radiation and Clinical Oncology Department, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch,Gliwice, PolandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Maria Sklodowska-Curie National Research Institute of Oncology
- Trial code
- NCT06472570
- Record updated
- 25 June 2024
- Original description
The goal of this study is to evaluate the safety and efficacy of the stereotactic boost applied in patients with H\&N tumours.Read full original descriptionShow less
Escalating a Biological Dose of Radiation in the Target Volume Applying Stereotactic Radiosurgery in Patients With Head and Neck Region Tumours
The goal of this study is to evaluate the safety and efficacy of the stereotactic boost applied in patients with H\&N tumours.
Inclusion: Patients with squamous cell carcinoma (SCC) or adenoid cystic carcinoma (ACC) of the H\&N region qualified for radical treatment with (definitive or adjuvant (adjuvant radiotherapy or radiochemotherapy in postoperative cases of R2 resection or early locoregional recurrence unsuitable for reoperation)) radiotherapy or radiochemotherapy; Patients with other malignant tumours of the H\&N region (sarcomas, neuroendocrine carcinomas, differentiated carcinomas, undifferentiated carcinomas, or basaloid carcinomas) qualified for radical treatment with (definitive or adjuvant (adjuvant radiotherapy or radiochemotherapy in postoperative cases of R2 resection or early locoregional recurrence unsuitable for reoperation)) radiotherapy or radiochemotherapy; Patients with nonmalignant tumours of the H\&N region (tumour mixtus or paraganglioma) demanding definitive or adjuvant radiotherapy; Age: 18-80 years. Biomedicines 2022, 10, 1484 5 of 12; Performance status: Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2; Conscious agreement to participate in the clinical trial.
Exclusion: Myocardial infarction occurred up to 6 months before; Decompensated diabetes mellitus; Mental disorder preclusive of making a conscious agreement; Do not meet the inclusion criteria; Pregnancy.